TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25564998

Group type: EXPERIMENTAL
Intervention: PO (5 min prior to exercise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IO (immediately prior to exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: CON (no occlusion during exercise)
Number of subjects: 0
Study: 24330860

Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Lurasidone 160 mg/d
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Quetiapine XR 600 mg/d
Number of subjects: 486

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 486
Study: 22544016

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg (started at 10 mg/d, increased to 20 mg/d after 4 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 40
Study: 20635355

Group type: EXPERIMENTAL
Intervention: Betaine and folic acid
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 48
Study: 18717089

Group type: EXPERIMENTAL
Intervention: Ti-15% Zr alloy crowns
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gold-palladium alloy crowns
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both crowns
Number of subjects: 20
Study: 15997019

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Fluoxetine hydrochloride
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Combination of cognitive-behavioral therapy and fluoxetine hydrochloride
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: High self-esteem
Number of subjects: 122

Group type: COMPARATOR
Intervention: Overall dropout rate
Number of subjects: 122
Study: 12622581

Group type: EXPERIMENTAL
Intervention: Invasive therapy (coronary angiography followed by revascularization if feasible)
Number of subjects: 282

Group type: COMPARATOR
Intervention: Optimized medical therapy
Number of subjects: 282
Study: 11138536

Group type: EXPERIMENTAL
Intervention: Tea ointment
Number of subjects: 104

Group type: COMPARATOR
Intervention: Soframycin (Framycetin and gramicidin)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Oral cephalexin
Number of subjects: 104
Study: 9178345

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment (once a week for a total of four sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Biofeedback treatment (after self-monitoring control period)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biofeedback treatment
Number of subjects: 30
Study: 8472155

Group type: EXPERIMENTAL
Intervention: Pyloroplasty
Number of subjects: 24

Group type: COMPARATOR
Intervention: No pyloroplasty
Number of subjects: 24
Study: 3620275

Group type: EXPERIMENTAL
Intervention: Isoxicam, 200 mg once daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ketoprofen, 100 mg three times daily
Number of subjects: 19
Study: 29783899

Group type: EXPERIMENTAL
Intervention: Tai Chi training
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Conventional exercise
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 28333990

Group type: EXPERIMENTAL
Intervention: Motivational intervention programme applied by teachers to support autonomy, competence, and relatedness.
Number of subjects: 921

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 921
Study: 25005017

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (running on a treadmill for 20 min at 60% of VO2 max)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (unrelated work for 40 min, then practicing peg transfer and pattern cut for 10 min, and intracorporeal suture for 15 min)
Number of subjects: 52
Study: 23298972

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Zinc plus iron-folic acid supplementation
Number of subjects: 544

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 544
Study: 22903851

Group type: EXPERIMENTAL
Intervention: Intervention condition (therapists and patients reviewed their respective ratings)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control condition (ratings given directly to the investigator without review)
Number of subjects: 16
Study: 18311688

Group type: EXPERIMENTAL
Intervention: Citalopram (0.4 mg/kg body weight, mean 31.96±4.45 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 23
Study: 16610924

Group type: EXPERIMENTAL
Intervention: Nurse-directed care (DMCP)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 367
Study: 12972469

Group type: EXPERIMENTAL
Intervention: Women with hip OA
Number of subjects: 508

Group type: COMPARATOR
Intervention: Men with hip OA
Number of subjects: 508
Study: 10476017

Group type: EXPERIMENTAL
Intervention: Presence of medical students during appointments
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Time spent alone with the doctor
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Centre B (longer appointments with students)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Lower social classes and older patients
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Presence of students
Number of subjects: 325
Study: 9084545

Group type: COMPARATOR
Intervention: Furosemide 30 mg i.v.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glycerol 0.5 g/kg i.v.
Number of subjects: 30
Study: 1651994

Group type: COMPARATOR
Intervention: VP‐16 (etoposide)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: VM‐26 (teniposide)
Number of subjects: 94
Study: 7058448

Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tube
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Method of investigation
Number of subjects: 0
Study: 30822621

Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 + Sorafenib 400 mg bid
Number of subjects: 102

Group type: COMPARATOR
Intervention: Docetaxel 100 mg/m2 + Placebo
Number of subjects: 102
Study: 28946838

Group type: EXPERIMENTAL
Intervention: Single 5 ml GO-ON injection
Number of subjects: 127

Group type: COMPARATOR
Intervention: Conventional three injections of 2.5 ml GO-ON at weekly intervals
Number of subjects: 127
Study: 25296729

Group type: EXPERIMENTAL
Intervention: Bite-Jumping Appliance (BJA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Twin-Block Appliance (TBA)
Number of subjects: 40
Study: 24456357

Group type: EXPERIMENTAL
Intervention: Laminaria japonica with LAB
Number of subjects: 40

Group type: COMPARATOR
Intervention: Laminaria japonica with placebo LAB
Number of subjects: 40
Study: 22394648

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide/formoterol (200 μg/12 μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide/salbutamol (200 μg/200 μg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 0
Study: 19958918

Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention programme (12 months duration)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 591
Study: 17537096

Group type: EXPERIMENTAL
Intervention: Medication review
Number of subjects: 452

Group type: COMPARATOR
Intervention: No medication review
Number of subjects: 452
Study: 15274752

Group type: EXPERIMENTAL
Intervention: Supplementation with antioxidants (vitamins C and E, beta-carotene, and selenium)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Methimazole only (Control group B)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Supplementation with antioxidants
Number of subjects: 57
Study: 11427243

Group type: EXPERIMENTAL
Intervention: 4-month collaborative care intervention provided by a trauma support specialist
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual posttraumatic care (Control)
Number of subjects: 34
Study: 9701099

Group type: EXPERIMENTAL
Intervention: 14-day triple therapy (30 mg of lansoprazole, 1 g of amoxicillin, and 500 mg of clarithromycin twice daily for 14 days)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: 10-day triple therapy (30 mg of lansoprazole, 1 g of amoxicillin, and 500 mg of clarithromycin twice daily for 10 days)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Adverse events related to therapy in 14-day group
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Adverse events related to therapy in 10-day group
Number of subjects: 236
Study: 7501140

Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Pemoline
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 2224165

Group type: EXPERIMENTAL
Intervention: IL2 alone or in combination with LAK cells, INF alpha or TNF
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: IL2 either alone or in combination with LAK cells
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: IL2
Number of subjects: 66
Study: 445326

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy-radiotherapy (CT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy-radiotherapy with radiation to involved fields (CTIF)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy-radiotherapy with total nodal radiation (CTTN)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Total nodal radiation followed by chemotherapy (TNCT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Total nodal radiation (TN)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Radiation +/− chemotherapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 107
Study: 31108227

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Golimumab
Number of subjects: 0
Study: 31120533

Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Partial Tinnitus Retraining Therapy (Partial TRT)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard of Care (SoC)
Number of subjects: 151
Study: 28570216

Group type: EXPERIMENTAL
Intervention: Highly crosslinked polyethylene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional polyethylene
Number of subjects: 0
Study: 25927657

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope (group A, n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: GlideScope (group G, n=35)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope (group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: GlideScope (group G)
Number of subjects: 70
Study: 24015915

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 1578

Group type: COMPARATOR
Intervention: No statin treatment (Control)
Number of subjects: 1578
Study: 21953205

Group type: EXPERIMENTAL
Intervention: Medications for the treatment of fibromyalgia (specific medications not detailed)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FM30 version 3 (short version)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: FM30 version 6 (long version)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19217105

Group type: EXPERIMENTAL
Intervention: Abdominal massage in addition to prescribed laxatives
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laxatives according to earlier prescriptions
Number of subjects: 60
Study: 17441849

Group type: EXPERIMENTAL
Intervention: Povidone iodine (PVP‐I) 100 mg/ml
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Povidone iodine (PVP‐I) 70 mg/ml
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 50 mg/ml
Number of subjects: 30

Group type: COMPARATOR
Intervention: Deionized water (control)
Number of subjects: 30
Study: 15259298

Group type: EXPERIMENTAL
Intervention: Routine medical testing (12-lead electrocardiogram, complete blood count, serum glucose measurements)
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Selective medical testing (no routine tests unless new or worsening medical problem)
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Routine medical testing
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Selective medical testing
Number of subjects: 1025
Study: 12361204

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10516870

Group type: EXPERIMENTAL
Intervention: trichlormethiazide
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: nicardipine
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: alacepril
Number of subjects: 33
Study: 7711988

Group type: EXPERIMENTAL
Intervention: Simvastatin 10-20 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 2791449

Group type: EXPERIMENTAL
Intervention: Oral verapamil (120 mg) and propranolol (80 mg) combined
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral verapamil (120 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Oral propranolol (80 mg)
Number of subjects: 8
Study: 780040

Group type: EXPERIMENTAL
Intervention: Ethosuximide given once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ethosuximide given 3 times daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single daily dose regimen
Number of subjects: 20
Study: 30478686

Group type: EXPERIMENTAL
Intervention: Laparoscopic washout
Number of subjects: 63

Group type: COMPARATOR
Intervention: Percutaneous drainage
Number of subjects: 63

Group type: COMPARATOR
Intervention: Open drainage
Number of subjects: 63
Study: 28789780

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (IncoA) injection
Number of subjects: 30
Study: 24570287

Group type: EXPERIMENTAL
Intervention: Intervention schools (N=292)
Number of subjects: 292

Group type: COMPARATOR
Intervention: Control schools (N=300)
Number of subjects: 292
Study: 23930743

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg for patients ≤65 years; 5 mg for patients >65 years)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST, 12 total sessions)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 21561899

Group type: EXPERIMENTAL
Intervention: Home-based exercise training
Number of subjects: 196

Group type: COMPARATOR
Intervention: Hospital-based exercise training
Number of subjects: 196
Study: 18565522

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Diane(35) Diario
Number of subjects: 34
Study: 16982785

Group type: EXPERIMENTAL
Intervention: 1,000 mg extended-release ciprofloxacin
Number of subjects: 12

Group type: COMPARATOR
Intervention: 500 mg levofloxacin
Number of subjects: 12
Study: 15327344

Group type: EXPERIMENTAL
Intervention: Mozart's Eine Kleine Nachtmusik
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: New Age Serenity Suite
Number of subjects: 63

Group type: COMPARATOR
Intervention: Popular recreational magazines
Number of subjects: 63
Study: 11377154

Group type: COMPARATOR
Intervention: Propofol 6 microg/mL
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Propofol 8 microg/mL
Number of subjects: 44
Study: 9406491

Group type: EXPERIMENTAL
Intervention: Green prescription (written exercise advice)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Verbal advice alone
Number of subjects: 25
Study: 8566633

Group type: EXPERIMENTAL
Intervention: etodolac 400 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: naproxen 500 mg b.i.d.
Number of subjects: 52

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 52
Study: 2598769

Group type: EXPERIMENTAL
Intervention: Ursodiol 250 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ursodiol 500 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ursodiol 750 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ursodiol administration in patients with initial serum bilirubin levels > 2 mg/dl
Number of subjects: 0
Study: 31774382

Group type: EXPERIMENTAL
Intervention: Negative stereotype toward women
Number of subjects: 77

Group type: COMPARATOR
Intervention: Nullified-stereotype
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control
Number of subjects: 77
Study: 30804309

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate followed by RMGIC
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide (Dycal)
Number of subjects: 54
Study: 28486043

Group type: COMPARATOR
Intervention: Azacitidine (75 mg/m2/day on days 1 to 7 of a 28-day cycle)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Azacitidine plus Lenalidomide (10 mg/day on days 1 to 21)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Azacitidine plus Vorinostat (300 mg twice daily on days 3 to 9)
Number of subjects: 277
Study: 26190726

Group type: EXPERIMENTAL
Intervention: Surgeon (operator)
Number of subjects: 321

Group type: COMPARATOR
Intervention: 1st assistant
Number of subjects: 321
Study: 23158882

Group type: EXPERIMENTAL
Intervention: PHiD-CV10 3+1 schedule
Number of subjects: 47369

Group type: EXPERIMENTAL
Intervention: PHiD-CV10 2+1 schedule
Number of subjects: 47369

Group type: COMPARATOR
Intervention: Control group (hepatitis vaccines)
Number of subjects: 47369

Group type: EXPERIMENTAL
Intervention: Combined PHiD-CV10 infant cohorts
Number of subjects: 47369

Group type: COMPARATOR
Intervention: Control cohorts
Number of subjects: 47369

Group type: COMPARATOR
Intervention: Catch-up cohorts (Control group)
Number of subjects: 47369
Study: 21756034

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing delivered by counselors with workshop‐only training
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing delivered by counselors with workshop training followed by peer group supervision
Number of subjects: 296

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 296
Study: 19402342

Group type: EXPERIMENTAL
Intervention: Ticlopidine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Internal standard (loratadine)
Number of subjects: 0
Study: 16986136

Group type: EXPERIMENTAL
Intervention: Intravesical instillation of 100 ml capsaicin diluted in glucidic solvent (CG)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Glucidic solvent alone (SG)
Number of subjects: 33
Study: 12763986

Group type: EXPERIMENTAL
Intervention: Clinical Terms Version 3
Number of subjects: 10

Group type: COMPARATOR
Intervention: Read Codes 5 byte set
Number of subjects: 10
Study: 10904458

Group type: EXPERIMENTAL
Intervention: Prepared meal plan
Number of subjects: 302
Study: 9253565

Group type: EXPERIMENTAL
Intervention: Berman intubating airway
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ovassapian intubating airway
Number of subjects: 65
Study: 7794292

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 3504357

Group type: EXPERIMENTAL
Intervention: In situ saphenous vein
Number of subjects: 100

Group type: COMPARATOR
Intervention: Reversed saphenous vein
Number of subjects: 100
Study: 29856793

Group type: EXPERIMENTAL
Intervention: Dermatoscope-acquired green channel intensity
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Dermatoscope-acquired blue channel intensity
Number of subjects: 64

Group type: COMPARATOR
Intervention: Directly applied pressure and dermatoscope without filter
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dermatoscope equipped with Wratten No. 11 filter
Number of subjects: 64
Study: 27731748

Group type: EXPERIMENTAL
Intervention: Ofatumumab plus fludarabine and cyclophosphamide (OFA + FC)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 365
Study: 26298642

Group type: EXPERIMENTAL
Intervention: Proficiency-based progression using the knot tester (Group C, n = 16)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard training (Group A, n = 14)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Workstation practice (Group B, n = 14)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Experienced surgeons (n = 30)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Faculty (n = 20)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Postgraduate year 4 or 5 residents (n = 44)
Number of subjects: 94
Study: 23597357

Group type: EXPERIMENTAL
Intervention: Home fecal immunochemical tests (FITs) offered during influenza vaccination clinics
Number of subjects: 6235

Group type: COMPARATOR
Intervention: No FIT offered (control group)
Number of subjects: 6235

Group type: EXPERIMENTAL
Intervention: Home fecal immunochemical tests (FITs) offered during influenza vaccination clinics (per protocol analysis)
Number of subjects: 6235

Group type: COMPARATOR
Intervention: No FIT offered (control group, per protocol analysis)
Number of subjects: 6235
Study: 21692400

Group type: EXPERIMENTAL
Intervention: Dementia Outreach Service (DEMOS) provided to 7 intervention facilities
Number of subjects: 320

Group type: COMPARATOR
Intervention: Control group of 13 facilities without DEMOS
Number of subjects: 320
Study: 18175062

Group type: EXPERIMENTAL
Intervention: Dual blockade (ACEI + ARB)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Single blockade (ARB)
Number of subjects: 86
Study: 16455629

Group type: EXPERIMENTAL
Intervention: 89SrCl2 therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 42
Study: 12701977

Group type: EXPERIMENTAL
Intervention: Cisplatin (40 mg/m2) concurrent with radiotherapy
Number of subjects: 39
Study: 11013775

Group type: EXPERIMENTAL
Intervention: Morphine (5 mg) injected periarticularly
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline injected periarticularly (Control)
Number of subjects: 32
Study: 8805740

Group type: EXPERIMENTAL
Intervention: Adenosine (0.140 mg/kg/min for 6 minutes)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Dipyridamole (0.142 mg/kg/min for 4 minutes)
Number of subjects: 54
Study: 1621888

Group type: EXPERIMENTAL
Intervention: Proguanil (200 mg/day) combined with dapsone (4 mg or 12.5 mg/day)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Pyrimethamine/dapsone (12.5 mg and 100 mg/week)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg/day)
Number of subjects: 438
Study: 6150856

Group type: EXPERIMENTAL
Intervention: S3341 (15 and 25 micrograms/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: S3341 (2 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 and 0.2 mg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13